Provided by Tiger Trade Technology Pte. Ltd.

CHINARES PHARMA

4.470
-0.100-2.19%
Volume:12.85M
Turnover:57.71M
Market Cap:28.09B
PE:5.95
High:4.600
Open:4.600
Low:4.470
Close:4.570
52wk High:6.336
52wk Low:4.211
Shares:6.28B
HK Float Shares:6.28B
Volume Ratio:1.20
T/O Rate:0.20%
Dividend:0.22
Dividend Rate:4.87%
EPS(LYR):0.751
ROE:8.32%
ROA:2.64%
PB:0.46
PE(LYR):5.95
PS:0.09

Loading ...

Stock Track | CHINARES PHARMA Soars 5.25% Intraday on Strong Earnings Results and Positive Outlook

Stock Track
·
Mar 27

CHINARES PHARMA Shares Extend Rally with Another 5% Gain

Stock News
·
Mar 27

CHINARES PHARMA Subsidiary Double-Crane Issues Up to RMB 1 Billion Corporate Bonds

Stock News
·
Mar 26

CR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon

Bulletin Express
·
Mar 26

CR Double-Crane issues 2026 corporate bonds; principal totals up to RMB1 billion at 1.65% coupon rate

Reuters
·
Mar 26

UBS Adjusts CHINARES PHARMA Target Price to HK$6.9, Citing In-Line Revenue and Above-Expectation Net Profit

Stock News
·
Mar 26

Stock Track | CHINARES PHARMA Soars 6.24% in Morning Session on Strong Annual Results with 20.73% Profit Jump

Stock Track
·
Mar 26

CHINARES PHARMA Shares Surge Over 6% in Morning Trading Following 20.73% Jump in Annual Net Profit

Deep News
·
Mar 26

BUZZ-China Resources Pharma hits more than 4-month peak on higher FY profit, dividend

Reuters
·
Mar 25

Stock Track | CHINARES PHARMA Soars 5.17% Intraday on Strong FY2025 Results That Beat Estimates

Stock Track
·
Mar 25

CHINARES PHARMA Reports Fiscal Year Profit Increase of 20.73% to 4.045 Billion Yuan

Stock News
·
Mar 25

China Resources Pharma proposes final dividend of RMB 0.122 per share

Reuters
·
Mar 25

China Resources Pharmaceutical - FY Profit Attributable RMB4.05 Bln

THOMSON REUTERS
·
Mar 25

China Resources Pharmaceutical Group - Final Dividend of RMB0.122 per Share

THOMSON REUTERS
·
Mar 25

China Resources Pharmaceutical FY2025 profit attributable to shareholders rose 20.7% to RMB4.05 billion

Reuters
·
Mar 25

CR Sanjiu 2025 net profit attributable to shareholders rises 1.58% to RMB3.42 billion

Reuters
·
Mar 20

CR Boya Bio-pharmaceutical 2025 Profit Drops 71.61%; Revenue Rises 18.69%—Subsidiary of CHINARES PHARMA

Bulletin Express
·
Mar 20

China Resources Pharma Reports 71.61% Net Profit Decline for Boya Bio-Pharmaceutical in 2025

Stock News
·
Mar 20

China Resources Pharmaceutical - FY Revenue RMB2.06 Bln for Cr Boya Bio-Pharmaceutical

THOMSON REUTERS
·
Mar 20

CR Boya Bio-pharmaceutical revenue rises 18.69% to RMB2.06 billion in 2025

Reuters
·
Mar 20